XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer

Nature

Volumn 538, Issue 7623, 2016, Pages 114-117

  Kim, Jimi ^a   McMillan, Elizabeth ^a   Kim, Hyun Seok ^b   Venkateswaran, Niranjan ^c   Makkar, Gurbani ^a   Rodriguez Canales, Aime ^d   Villalobos, Pamela ^d   Neggers, Jasper Edgar ^e   Mendiratta, Saurabh ^a   Wei, Shuguang ^c   Landesman, Yosef ^f   Senapedis, William ^f   Baloglu, Erkan ^f   Chow, Chi Wan B ^d   Frink, Robin E ^a   Gao, Boning ^a   Roth, Michael ^c   Minna, John D ^a   Daelemans, Dirk ^e   Wistuba, Ignacio I ^d   Posner, Bruce A ^c   Scaglioni, Pier Paolo ^c   White, Michael A ^a   more..

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Yonsei University College of Medicine   (South Korea)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f Karyopharm Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXPORTIN 1; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR YAP1; CELL RECEPTOR; DNA BINDING PROTEIN; EXPORTIN 1 PROTEIN; FOLLISTATIN RELATED PROTEIN; FSTL5 PROTEIN, HUMAN; HIPPO PROTEIN, HUMAN; I KAPPA B KINASE ALPHA; KARYOPHERIN; KRAS PROTEIN, HUMAN; NUCLEAR PROTEIN; PHOSPHOPROTEIN; PORPHYRIN; PROTEIN P21; PROTEIN SERINE THREONINE KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TEAD1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; VERTEPORFIN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

CANCER; CELLS AND CELL COMPONENTS; CHEMICAL ANALYSIS; ENZYME ACTIVITY; GENE; GENOMICS; MUTATION; PROTEIN; VULNERABILITY;

ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; GENE INTERACTION; GENE MUTATION; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; NON SMALL CELL LUNG CANCER; NUCLEAR EXPORT SIGNAL; ONCOGENE K RAS; PHENOTYPIC VARIATION; PRIORITY JOURNAL; ACTIVE TRANSPORT; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CELL NUCLEUS; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENETICS; LETHAL GENE; LUNG NEOPLASMS; METABOLISM; MOUSE; MUTATION; PATHOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; DNA-BINDING PROTEINS; FEMALE; FOLLISTATIN-RELATED PROTEINS; GENES, LETHAL; HUMANS; KARYOPHERINS; LUNG NEOPLASMS; MICE; MUTATION; NF-KAPPA B; NF-KAPPAB INHIBITOR ALPHA; NUCLEAR PROTEINS; PHOSPHOPROTEINS; PORPHYRINS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84990229688     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature19771     Document Type: Article

References (35)

1. Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. Drugging the undruggable RAS: mission possible? Nat. Rev. Drug Discov. 13, 828-851 (2014
2. Barbie, D. A., et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108-112 (2009
3. Luo, J., et al A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the RAS oncogene. Cell 137, 835-848 (2009
4. Kumar, M. S., et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149, 642-655 (2012
5. Scholl, C., et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137, 821-834 (2009
6. Frey, B. J., & Dueck, D. Clustering by passing messages between data points. Science 315, 972-976 (2007
7. Kim, H. S., et al. Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell 155, 552-566 (2013
8. Whitehurst, A. W., et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446, 815-819 (2007
9. Jackson, A. L., et al. Widespread siRNA 'off-Target' transcript silencing mediated by seed region sequence complementarity. RNA 12, 1179-1187 (2006
10. Etchin, J., et al. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br. J. Haematol. 161, 117-127 (2013
11. Lapalombella, R., et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood 120, 4621-4634 (2012
12. Neggers, J. E., et al. Identifying drug-Target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing. Chem. Biol. 22, 107-116 (2015
13. Abdul Razak, A. R., et al. First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2015.65.3949 (2016
14. Cheng, Y., et al. XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer. Mol. Cancer Ther. 13, 675-686 (2014
15. Meylan, E., et al. Requirement for NF-? B signalling in a mouse model of lung adenocarcinoma. Nature 462, 104-107 (2009
16. Bassères, D. S., Ebbs, A., Cogswell, P. C., & Baldwin, A. S. IKK is a therapeutic target in KRAS-induced lung cancer with disrupted p53 activity. Genes Cancer 5, 41-55 (2014
17. Wuerzberger-Davis, S. M., et al. Nuclear export of the NF-? B inhibitor I? Bα is required for proper B cell and secondary lymphoid tissue formation. Immunity 34, 188-200 (2011
18. Burke, J. R., et al. BMS-345541 is a highly selective inhibitor of I?B kinase that binds at an allosteric site of the enzyme and blocks NF-?B-dependent transcription in mice. J. Biol. Chem. 278, 1450-1456 (2003
19. Zender, L., et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135, 852-864 (2008
20. Fitamant, J., et al. YAP inhibition restores hepatocyte differentiation in advanced HCC, leading to tumor regression. Cell Rep. 10, 1692-1707 (2015
21. Kapoor, A., et al. YAP1 activation enables bypass of oncogenic KRAS addiction in pancreatic cancer. Cell 158, 185-197 (2014
22. Lin, L., et al. The Hippo effector YAP promotes resistance to RAF-And MEK-Targeted cancer therapies. Nat. Genet. 47, 250-256 (2015
23. Shao, D. D., et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 158, 171-184 (2014
24. Yu, F.X., Zhao, B., & Guan, K.L. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell 163, 811-828(2015
25. Mo, J. S., et al. Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway. Nat. Cell Biol. 17, 500-510 (2015
26. Singh, N. K., Seo, B. Y., Vidyasagar, M., White, M. A., & Kim, H. S. siMacro: a fast and easy data processing tool for cell-based genomewide siRNA screens. Genomics Inform. 11, 55-57 (2013
27. Shigematsu, H., et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 65, 1642-1646 (2005
28. Yamamoto, H., et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res. 68, 6913-6921 (2008
29. Phelps, R. M., et al. NCI-Navy Medical Oncology Branch cell line data base. J. Cell. Biochem. Suppl. 24, 32-91 (1996
30. Shigematsu, H., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst. 97, 339-346 (2005
31. Shannon, P., et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498-2504 (2003
32. Bruckova, L., et al. Proliferative potential and phenotypic analysis of long-Term cultivated human granulosa cells initiated by addition of follicular fluid. J. Assist. Reprod. Genet. 28, 939-950 (2011
33. DuPage, M., Dooley, A. L., & Jacks, T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protocols 4, 1064-1072 (2009
34. Sun, M., et al. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin. Cancer Res. 15, 4829-4837 (2009
35. Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. Ultrafast and memoryefficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009